Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Prostate-Specific Membrane Antigen PET/Magnetic Resonance Imaging for the Planning of Salvage Radiotherapy in Patients with Prostate Cancer with Biochemical Recurrence After Radical Prostatectomy.

Elschot M, Selnæs KM, Langørgen S, Johansen H, Bertilsson H, Tandstad T, Bathen TF.

PET Clin. 2019 Oct;14(4):487-498. doi: 10.1016/j.cpet.2019.06.003. Epub 2019 Aug 2. Review.

PMID:
31472746
2.

68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning.

Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler K, Chu FI, King CR, Steinberg ML, Rauscher I, Schmidt-Hegemann NS, Poeppel T, Hetkamp P, Ceci F, Herrmann K, Fendler WP, Eiber M, Nickols NG.

J Nucl Med. 2018 Feb;59(2):230-237. doi: 10.2967/jnumed.117.201749. Epub 2017 Nov 9.

3.

Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy.

Schmidt-Hegemann NS, Fendler WP, Ilhan H, Herlemann A, Buchner A, Stief C, Eze C, Rogowski P, Li M, Bartenstein P, Ganswindt U, Belka C.

Radiat Oncol. 2018 Mar 2;13(1):37. doi: 10.1186/s13014-018-0983-4.

4.

68 Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment.

Habl G, Sauter K, Schiller K, Dewes S, Maurer T, Eiber M, Combs SE.

Prostate. 2017 Jun;77(8):920-927. doi: 10.1002/pros.23347. Epub 2017 Mar 20.

PMID:
28317152
5.

Prognostic factors after salvage radiotherapy alone in patients with biochemical recurrence after radical prostatectomy.

Song W, Jeon HG, Sung HH, Jeong BC, Seo SI, Jeon SS, Choi HY, Lee HM.

Int J Urol. 2016 Jan;23(1):56-61. doi: 10.1111/iju.12960. Epub 2015 Oct 26.

6.

Outcome after PSMA PET/CT based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: a bi-institutional retrospective analysis.

Schmidt-Hegemann NS, Stief C, Kim TH, Eze C, Kirste S, Strouthos I, Li M, Schultze-Seemann W, Ilhan H, Fendler WP, Bartenstein P, Grosu AL, Ganswindt U, Belka C, Meyer PT, Zamboglou C.

J Nucl Med. 2018 Jul 12. pii: jnumed.118.212563. doi: 10.2967/jnumed.118.212563. [Epub ahead of print]

7.

68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy.

Farolfi A, Ceci F, Castellucci P, Graziani T, Siepe G, Lambertini A, Schiavina R, Lodi F, Morganti AG, Fanti S.

Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):11-19. doi: 10.1007/s00259-018-4066-4. Epub 2018 Jun 15.

PMID:
29905907
8.

[Diagnostic performance of 68GA-PSMA PET/CTin patients with prostate cancer].

Veliev EI, Tomilov AA, Goncharuk DA, Bogdanov AB, Golubtsova EN.

Urologiia. 2018 Jul;(3):105-110. Russian.

PMID:
30035428
9.

The Utility of PET/CT in the Planning of External Radiation Therapy for Prostate Cancer.

Calais J, Cao M, Nickols NG.

J Nucl Med. 2018 Apr;59(4):557-567. doi: 10.2967/jnumed.117.196444. Epub 2018 Jan 4.

10.

Patterns of failure after radical prostatectomy in prostate cancer - implications for radiation therapy planning after 68Ga-PSMA-PET imaging.

Schiller K, Sauter K, Dewes S, Eiber M, Maurer T, Gschwend J, Combs SE, Habl G.

Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1656-1662. doi: 10.1007/s00259-017-3746-9. Epub 2017 Jun 23.

PMID:
28646463
11.

Multiparametric Magnetic Resonance Imaging Is an Independent Predictor of Salvage Radiotherapy Outcomes After Radical Prostatectomy.

Sharma V, Nehra A, Colicchia M, Westerman ME, Kawashima A, Froemming AT, Kwon ED, Mynderse LA, Karnes RJ.

Eur Urol. 2018 Jun;73(6):879-887. doi: 10.1016/j.eururo.2017.11.012. Epub 2017 Nov 28.

PMID:
29195777
12.

Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].

Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG.

BMC Cancer. 2019 Jan 7;19(1):18. doi: 10.1186/s12885-018-5200-1. Erratum in: BMC Cancer. 2019 Jan 21;19(1):97.

13.

Patterns of relapse as determined by 68Ga-PSMA ligand PET/CT after radical prostatectomy : Importance for tailoring and individualizing treatment.

Henkenberens C, Derlin T, Bengel FM, Ross TL, Wester HJ, Hueper K, Kuczyk MA, Christiansen H, von Klot CA.

Strahlenther Onkol. 2018 Apr;194(4):303-310. doi: 10.1007/s00066-017-1231-9. Epub 2017 Nov 13.

PMID:
29134231
14.

The use of 68  Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer.

Meredith G, Wong D, Yaxley J, Coughlin G, Thompson L, Kua B, Gianduzzo T.

BJU Int. 2016 Oct;118 Suppl 3:49-55. doi: 10.1111/bju.13616. Epub 2016 Sep 23.

15.

Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.

Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, Walsh PC.

JAMA. 2008 Jun 18;299(23):2760-9. doi: 10.1001/jama.299.23.2760.

16.

Prospective comparison of whole-body MRI and 68Ga-PSMA PET/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy.

Sawicki LM, Kirchner J, Buddensieck C, Antke C, Ullrich T, Schimmöller L, Boos J, Schleich C, Schaarschmidt BM, Buchbender C, Heusch P, Rabenalt R, Albers P, Antoch G, Müller HW, Hautzel H.

Eur J Nucl Med Mol Imaging. 2019 Jul;46(7):1542-1550. doi: 10.1007/s00259-019-04308-5. Epub 2019 Mar 16.

PMID:
30879122
17.

Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy.

Rauscher I, Düwel C, Haller B, Rischpler C, Heck MM, Gschwend JE, Schwaiger M, Maurer T, Eiber M.

Eur Urol. 2018 May;73(5):656-661. doi: 10.1016/j.eururo.2018.01.006. Epub 2018 Jan 19.

PMID:
29358059
18.

Treatment Outcomes from 68Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET.

Emmett L, van Leeuwen PJ, Nandurkar R, Scheltema MJ, Cusick T, Hruby G, Kneebone A, Eade T, Fogarty G, Jagavkar R, Nguyen Q, Ho B, Joshua AM, Stricker P.

J Nucl Med. 2017 Dec;58(12):1972-1976. doi: 10.2967/jnumed.117.196683. Epub 2017 Jul 26.

19.

68Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: Current state and future trends.

Udovicich C, Perera M, Hofman MS, Siva S, Del Rio A, Murphy DG, Lawrentschuk N.

Prostate Int. 2017 Dec;5(4):125-129. doi: 10.1016/j.prnil.2017.02.003. Epub 2017 Feb 24. Review.

20.

68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy.

Ceci F, Castellucci P, Graziani T, Farolfi A, Fonti C, Lodi F, Fanti S.

Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):31-39. doi: 10.1007/s00259-018-4189-7. Epub 2018 Oct 22.

PMID:
30350010

Supplemental Content

Support Center